The randomized phase III RATIFY trial demonstrated the efficacy of midostaurin in combination with the standard backbone regimen of cytarabine and daunorubicin (3/7) induction and high‐dose cytarabine consolidation in patients younger than 60 years with previously untreated FLT3 (internal tandem duplication (ITD) and/or tyrosine kinase domain (TKD) mutated) AML [2]. The gene discussed is FLT3; the disease is acute myeloid leukemia.